Tracking the culprits of insulin resistance 19 February 2018 Lipids are molecules that form the building blocks of the cells comprising our bodies. When some lipids build up, especially in the liver and the muscles, it can lead to insulin resistance. This can lead to type 2 diabetes. Scientists don’t know exactly which lipids trigger insulin resistance, but they have a couple of prime suspects. Associate Professor Nigel Turner from the University of New South Wales has one lipid, C18:0 ceramide, firmly in his sites and thanks to a grant from the Diabetes Australia Research Trust he will be able to investigate further. “Recent studies in animals and humans have shown that insulin resistance in muscle is closely associated with the build-up of C18:0 ceramide,” Associate Professor Turner said. “We have developed some compounds which target the enzymes responsible for producing C:18:0 ceramide, so we want to see if reducing the amount of this lipid could also reduce insulin resistance. “We hope it leads to more effective treatments for people with type 2 diabetes.” Associate Professor Turner’s research is supported by Diabetes Australia through the Diabetes Australia Research Trust. Find out how you can help support research projects like this here.
Media releases 20 February 2026 Diabetes Australia appoints first Chief Health Officer Diabetes Australia has appointed Brett Fenton as its first Chief Health Officer marking a major step in strengthening clinical leadership and improving outcomes for people living with diabetes. Continue Reading
Blog 18 February 2026 Introducing the new Diabetes Shop: Your diabetes care, made easier We’re thrilled to share something we’ve been working on behind the scenes: your Diabetes Shop has a brand‑new look, designed with you in mind. Come take a look... Continue Reading
Media releases 17 February 2026 Innovative diabetes research grants will prioritise lived experiences and improve lives Innovative research projects that leverage AI technology, reduce diabetes complications, and seek to preserve and restore beta cell function are set for a $2 million investment in 2026 through the Diabetes Australia Research Trust. Continue Reading